Product Pipeline

Microbiome Therapeutics Pipeline
Microbiome Pharmaceuticals Discovery
Clinical program

Phase 1b/2a: MH002 - ulcerative colitis, ongoing expansion across gut inflammation.

Read More
Microbiome OTC Nutrition Probiotics
Preclinical programs

Parkinson’s and metabolic diseases (co-development with IFF, formerly DuPont).

Consumer Probiotics Microbiome Nutritional Therapies
Discovery programs

Ongoing program in spondylarthritis and autoimmune conditions.



Targeting both the Pharma
and the OTC markets

By combining highly skilled scientists from different disciplines with an extensive in house technology platform, relevant market insights and sufficient financial means, MRM Health is in the unique position to exploit its expertise in gut physiology and microbiology for setting up a differentiating product development activity based on the use of live bacteria.

Contact us